Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Antigens, Differentiation, Myelomonocytic | 3 | 2021 | 198 | 1.02 | Why? |
| Lipopolysaccharide Receptors | 2 | 2021 | 357 | 0.86 | Why? |
| Receptors, Cell Surface | 3 | 2021 | 586 | 0.80 | Why? |
| Antigens, CD | 4 | 2021 | 984 | 0.77 | Why? |
| Myeloid Cells | 1 | 2021 | 808 | 0.60 | Why? |
| Dendritic Cells | 1 | 2021 | 1330 | 0.47 | Why? |
| Monocytes | 2 | 2021 | 2978 | 0.43 | Why? |
| Interferon-alpha | 1 | 2017 | 1442 | 0.38 | Why? |
| Hepatitis C | 2 | 2017 | 1514 | 0.37 | Why? |
| Hepacivirus | 1 | 2017 | 1509 | 0.34 | Why? |
| Tuberculosis, Meningeal | 2 | 2018 | 100 | 0.31 | Why? |
| Inflammation Mediators | 1 | 2017 | 2654 | 0.30 | Why? |
| Anti-HIV Agents | 4 | 2018 | 2209 | 0.28 | Why? |
| Biomarkers | 6 | 2021 | 23361 | 0.23 | Why? |
| Hepatitis B virus | 2 | 2019 | 882 | 0.22 | Why? |
| Hepatitis B | 2 | 2019 | 888 | 0.21 | Why? |
| NADPH Oxidase 2 | 1 | 2020 | 58 | 0.21 | Why? |
| Receptors, OX40 | 1 | 2019 | 6 | 0.20 | Why? |
| Hepatitis B Surface Antigens | 2 | 2019 | 305 | 0.20 | Why? |
| HIV Infections | 7 | 2018 | 11620 | 0.20 | Why? |
| Selenoprotein P | 1 | 2018 | 40 | 0.19 | Why? |
| Natural Killer T-Cells | 1 | 2020 | 191 | 0.19 | Why? |
| alpha-2-HS-Glycoprotein | 1 | 2018 | 25 | 0.18 | Why? |
| Hepatitis Delta Virus | 1 | 2018 | 54 | 0.18 | Why? |
| Microbial Interactions | 1 | 2018 | 67 | 0.18 | Why? |
| Hepatitis C, Chronic | 2 | 2018 | 973 | 0.18 | Why? |
| Darunavir | 2 | 2018 | 477 | 0.18 | Why? |
| Matrix Metalloproteinase 2 | 1 | 2018 | 85 | 0.17 | Why? |
| Interleukin-2 Receptor alpha Subunit | 1 | 2019 | 234 | 0.17 | Why? |
| Adiponectin | 1 | 2018 | 123 | 0.17 | Why? |
| Hepatitis C Antibodies | 1 | 2017 | 120 | 0.16 | Why? |
| Matrix Metalloproteinase 9 | 1 | 2018 | 211 | 0.16 | Why? |
| Atazanavir Sulfate | 1 | 2018 | 213 | 0.16 | Why? |
| Interferon-gamma Release Tests | 1 | 2019 | 253 | 0.16 | Why? |
| Reverse Transcriptase Inhibitors | 1 | 2018 | 309 | 0.16 | Why? |
| Measles virus | 1 | 2018 | 194 | 0.16 | Why? |
| Antigens, Bacterial | 1 | 2019 | 330 | 0.15 | Why? |
| Klebsiella Infections | 1 | 2020 | 466 | 0.15 | Why? |
| Thalidomide | 1 | 2018 | 247 | 0.15 | Why? |
| Astrocytes | 1 | 2018 | 298 | 0.15 | Why? |
| CD4 Lymphocyte Count | 2 | 2017 | 1517 | 0.14 | Why? |
| Virus Activation | 1 | 2019 | 480 | 0.14 | Why? |
| Case-Control Studies | 4 | 2021 | 17671 | 0.13 | Why? |
| Chemokine CXCL10 | 1 | 2017 | 565 | 0.12 | Why? |
| Up-Regulation | 1 | 2021 | 2249 | 0.12 | Why? |
| Mycobacterium tuberculosis | 2 | 2019 | 1164 | 0.12 | Why? |
| Hepatitis B, Chronic | 1 | 2019 | 616 | 0.12 | Why? |
| Antitubercular Agents | 1 | 2018 | 775 | 0.11 | Why? |
| Measles | 1 | 2018 | 608 | 0.10 | Why? |
| Immunosuppressive Agents | 2 | 2019 | 6331 | 0.10 | Why? |
| Phenotype | 1 | 2021 | 4037 | 0.10 | Why? |
| Chilblains | 1 | 2020 | 1156 | 0.10 | Why? |
| Anti-Retroviral Agents | 1 | 2018 | 1099 | 0.09 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 9335 | 0.09 | Why? |
| Thromboembolism | 1 | 2021 | 2101 | 0.09 | Why? |
| Diabetes Mellitus, Type 2 | 2 | 2020 | 6166 | 0.09 | Why? |
| Female | 26 | 2021 | 380317 | 0.08 | Why? |
| Lymphocyte Activation | 1 | 2017 | 2742 | 0.08 | Why? |
| Mortality | 2 | 2021 | 7132 | 0.08 | Why? |
| Middle Aged | 20 | 2021 | 270681 | 0.08 | Why? |
| Male | 23 | 2021 | 367725 | 0.08 | Why? |
| Coronary Artery Disease | 1 | 2021 | 2570 | 0.08 | Why? |
| CD4-CD8 Ratio | 2 | 2018 | 235 | 0.08 | Why? |
| HIV-1 | 2 | 2018 | 3365 | 0.08 | Why? |
| Renal Insufficiency, Chronic | 1 | 2020 | 2654 | 0.08 | Why? |
| Antiviral Agents | 3 | 2018 | 41703 | 0.08 | Why? |
| Liver Cirrhosis | 1 | 2017 | 1810 | 0.07 | Why? |
| Disease Progression | 2 | 2021 | 13580 | 0.07 | Why? |
| Evolution, Molecular | 1 | 2018 | 3691 | 0.07 | Why? |
| Outpatients | 1 | 2017 | 3417 | 0.07 | Why? |
| Patient Admission | 1 | 2021 | 5250 | 0.07 | Why? |
| Italy | 8 | 2020 | 38444 | 0.07 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2021 | 5164 | 0.07 | Why? |
| Ritonavir | 1 | 2018 | 4212 | 0.06 | Why? |
| Aged, 80 and over | 7 | 2021 | 88759 | 0.06 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 3832 | 0.06 | Why? |
| Tuberculosis | 1 | 2019 | 2895 | 0.06 | Why? |
| Immunity, Innate | 1 | 2021 | 6570 | 0.06 | Why? |
| Viral Load | 3 | 2019 | 15850 | 0.06 | Why? |
| Aged | 12 | 2021 | 215776 | 0.06 | Why? |
| Adult | 15 | 2021 | 244371 | 0.06 | Why? |
| Coinfection | 2 | 2018 | 6820 | 0.05 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2018 | 5837 | 0.05 | Why? |
| Humans | 28 | 2021 | 930598 | 0.05 | Why? |
| Validation Studies as Topic | 1 | 2020 | 121 | 0.05 | Why? |
| Ear Auricle | 1 | 2020 | 62 | 0.05 | Why? |
| Host-Pathogen Interactions | 1 | 2021 | 11041 | 0.05 | Why? |
| Interleukin-6 | 1 | 2018 | 7522 | 0.05 | Why? |
| Anti-Bacterial Agents | 1 | 2020 | 10083 | 0.05 | Why? |
| Diabetes Mellitus | 1 | 2020 | 8207 | 0.04 | Why? |
| Thrombosis | 1 | 2020 | 7504 | 0.04 | Why? |
| Observer Variation | 1 | 2020 | 622 | 0.04 | Why? |
| Hydrocephalus | 1 | 2018 | 139 | 0.04 | Why? |
| Odds Ratio | 2 | 2021 | 5861 | 0.04 | Why? |
| Emtricitabine | 1 | 2018 | 202 | 0.04 | Why? |
| Raltegravir Potassium | 1 | 2018 | 132 | 0.04 | Why? |
| HIV Protease Inhibitors | 1 | 2000 | 434 | 0.04 | Why? |
| Prospective Studies | 5 | 2021 | 43301 | 0.04 | Why? |
| Immunocompetence | 1 | 2018 | 280 | 0.04 | Why? |
| Cerebrospinal Fluid | 1 | 2018 | 234 | 0.04 | Why? |
| Genotype | 2 | 2019 | 4697 | 0.04 | Why? |
| Primary Cell Culture | 1 | 2018 | 501 | 0.04 | Why? |
| Off-Label Use | 1 | 2020 | 553 | 0.04 | Why? |
| Rats, Wistar | 1 | 2018 | 621 | 0.04 | Why? |
| Antiretroviral Therapy, Highly Active | 2 | 2017 | 952 | 0.04 | Why? |
| Rome | 1 | 2017 | 497 | 0.04 | Why? |
| Cardiovascular Diseases | 1 | 2020 | 11497 | 0.04 | Why? |
| Multimorbidity | 1 | 2020 | 703 | 0.04 | Why? |
| Rhodococcus equi | 1 | 1994 | 2 | 0.04 | Why? |
| Actinomycetales Infections | 1 | 1994 | 10 | 0.04 | Why? |
| Cohort Studies | 4 | 2021 | 36005 | 0.04 | Why? |
| Leukocytosis | 1 | 2017 | 280 | 0.04 | Why? |
| Metabolic Diseases | 1 | 2020 | 505 | 0.04 | Why? |
| Klebsiella pneumoniae | 1 | 2020 | 658 | 0.04 | Why? |
| Tenofovir | 1 | 2018 | 449 | 0.03 | Why? |
| Genetic Variation | 2 | 2019 | 3919 | 0.03 | Why? |
| beta-Lactamases | 1 | 2020 | 759 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2021 | 2437 | 0.03 | Why? |
| Treatment Outcome | 4 | 2021 | 51732 | 0.03 | Why? |
| Severity of Illness Index | 1 | 2021 | 48226 | 0.03 | Why? |
| Milk, Human | 1 | 2021 | 956 | 0.03 | Why? |
| Cell Survival | 1 | 2018 | 1581 | 0.03 | Why? |
| Bacterial Proteins | 1 | 2020 | 1318 | 0.03 | Why? |
| Microbial Sensitivity Tests | 1 | 2020 | 2886 | 0.03 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.03 | Why? |
| Reactive Oxygen Species | 1 | 2018 | 1136 | 0.03 | Why? |
| Kaplan-Meier Estimate | 1 | 2021 | 4260 | 0.03 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 1994 | 260 | 0.03 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.03 | Why? |
| Mothers | 1 | 2021 | 1624 | 0.03 | Why? |
| Breast Feeding | 1 | 2021 | 1585 | 0.03 | Why? |
| Follow-Up Studies | 2 | 2020 | 17020 | 0.03 | Why? |
| Antibodies, Bacterial | 1 | 1994 | 510 | 0.03 | Why? |
| Apoptosis | 1 | 2000 | 2335 | 0.03 | Why? |
| Peptide Fragments | 1 | 2020 | 2075 | 0.02 | Why? |
| Oxidative Stress | 1 | 2020 | 2050 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2021 | 6543 | 0.02 | Why? |
| Flow Cytometry | 1 | 2017 | 2393 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2020 | 4020 | 0.02 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.02 | Why? |
| Protein Conformation | 1 | 2018 | 4386 | 0.02 | Why? |
| Sensitivity and Specificity | 2 | 2019 | 22971 | 0.02 | Why? |
| Feces | 1 | 2020 | 4235 | 0.02 | Why? |
| Incidence | 2 | 2020 | 25622 | 0.02 | Why? |
| Logistic Models | 1 | 2021 | 9089 | 0.02 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 5993 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2018 | 7268 | 0.02 | Why? |
| Retrospective Studies | 3 | 2021 | 105322 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2021 | 7972 | 0.02 | Why? |
| Intensive Care Units | 2 | 2021 | 29594 | 0.02 | Why? |
| Models, Molecular | 1 | 2018 | 7616 | 0.02 | Why? |
| Neutrophils | 1 | 2000 | 5476 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2018 | 9893 | 0.01 | Why? |
| Immunocompromised Host | 1 | 2019 | 5150 | 0.01 | Why? |
| Glucocorticoids | 1 | 2018 | 4431 | 0.01 | Why? |
| Nasopharynx | 1 | 2021 | 10224 | 0.01 | Why? |
| Predictive Value of Tests | 1 | 2017 | 9537 | 0.01 | Why? |
| Magnetic Resonance Imaging | 1 | 2018 | 6551 | 0.01 | Why? |
| Chemotaxis, Leukocyte | 1 | 2000 | 82 | 0.01 | Why? |
| Brain | 1 | 2018 | 5133 | 0.01 | Why? |
| Ambulatory Care | 1 | 2017 | 4947 | 0.01 | Why? |
| Infant, Newborn | 1 | 2021 | 23105 | 0.01 | Why? |
| Risk Factors | 2 | 2020 | 71621 | 0.01 | Why? |
| Viral Proteins | 1 | 2018 | 7370 | 0.01 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.01 | Why? |
| Phylogeny | 1 | 2018 | 13341 | 0.01 | Why? |
| Child | 2 | 2018 | 70012 | 0.01 | Why? |
| Mutation | 1 | 2018 | 12376 | 0.01 | Why? |
| In Vitro Techniques | 1 | 2000 | 1027 | 0.01 | Why? |
| Prognosis | 1 | 2020 | 32490 | 0.01 | Why? |
| Inflammation | 1 | 2018 | 13255 | 0.01 | Why? |
| Prevalence | 1 | 2017 | 25773 | 0.01 | Why? |
| Stroke | 1 | 2018 | 8839 | 0.01 | Why? |
| Pneumonia | 1 | 1994 | 5652 | 0.01 | Why? |
| Immunoblotting | 1 | 1994 | 180 | 0.01 | Why? |
| Comorbidity | 1 | 2017 | 34796 | 0.01 | Why? |
| Pandemics | 4 | 2020 | 389249 | 0.01 | Why? |
| RNA, Viral | 1 | 2018 | 32276 | 0.01 | Why? |
| Animals | 1 | 2018 | 78931 | 0.01 | Why? |
| Young Adult | 1 | 2018 | 93724 | 0.01 | Why? |
| Antibody Formation | 1 | 1994 | 4038 | 0.00 | Why? |